TIDMAVCT

RNS Number : 5988B

Avacta Group PLC

08 October 2015

08 October 2015

Avacta Group plc

("Avacta" or "the Group")

Notice of Results

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, expects to announce its preliminary results for the year ended 31 July 2015 on Monday 26 October 2015.

Enquiries:

 
 Avacta Group plc                                 Tel: +44 (0) 844 414 
  Alastair Smith, Chief Executive Officer          0452 
  Tim Sykes, Chief Financial Officer               www.avacta.com 
 Numis Securities Limited                         Tel: +44 (0) 207 260 
  Michael Meade / Freddie Barnfield - Nominated    1000 
  Adviser                                          www.numiscorp.com 
  James Black - Corporate Broking 
 
  WG Partners                                      Tel: +44 (0) 203 705 
  David Wilson                                     9318 
  Nigel Barnes                                     Tel: +44 (0) 203 705 
  Claes Spang                                      9217 
                                                   www.wgpartners.co.uk 
 Media Enquiries                                  Tel: +44 (0) 20 3727 
  FTI Consulting                                   1000 
  Simon Conway/Natalie Garland-Collins             avacta@fticonsulting.com

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimers have been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimers are based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta is commercialising Affimer reagents through custom Affimer services to provide bespoke solutions to customers, via a growing on-line catalogue of Affimer reagents and, in the longer term, by developing Affimers with therapeutic properties for out-licensing.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORFSAFWWFISEES

(END) Dow Jones Newswires

October 08, 2015 02:00 ET (06:00 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avacta Charts.